PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of wtpaEurope PMCEurope PMC Funders GroupSubmit a Manuscript
 
Science. Author manuscript; available in PMC 2007 June 19.
Published in final edited form as:
PMCID: PMC1892797
EMSID: UKMS492

Nucleus Accumbens D2/3 Receptors Predict Trait Impulsivity and Cocaine Reinforcement

Abstract

Stimulant addiction is often linked to excessive risk taking, sensation seeking, and impulsivity, but in ways that are poorly understood. We report here that a form of impulsivity in rats predicts high rates of intravenous cocaine self-administration and is associated with changes in dopamine (DA) function before drug exposure. Using positron emission tomography, we demonstrated that D2/3 receptor availability is significantly reduced in the nucleus accumbens of impulsive rats that were never exposed to cocaine and that such effects are independent of DA release. These data demonstrate that trait impulsivity predicts cocaine reinforcement and that D2 receptor dysfunction in abstinent cocaine addicts may, in part, be determined by premorbid influences.

Accumulating evidence suggests that certain personality traits, including sensation (or novelty) seeking, impulsivity, and antisocial conduct disorder, may predispose humans to drug abuse and addiction (1-4). However, from studies of human drug addicts alone, it is difficult to determine whether comorbid impulsivity and cognitive dysfunction (5, 6) pre-date the onset of drug use or emerge as a consequence of chronic drug use. Current hypotheses suggest that long-term drug use impairs inhibitory control functions mediated by the prefrontal cortex and the associated limbic brain circuitry, leading to a loss of inhibition or to impulsivity (7, 8). However, there is little evidence to date that chronic exposure to cocaine and other psychostimulant drugs leads to long-term increases in impulsive behavior in animals (9-11).

The view that individual differences in drug abuse reflect distinct behavioral and physiological traits is richly supported by studies in animals (12-17). Rats that are selected for high novelty-induced locomotor activity more readily acquire intravenous amphetamine and cocaine self-administration at lower doses than do rats that show reduced levels of activity (12, 13). In addition, rats that are impulsive on a delay-of-reward task, choosing a small immediate reward over a large but delayed reward, show an increased propensity to self-administer cocaine, as compared to low-impulsive rats (18). Finally, the existence of trait variables related to drug-abuse vulnerability is encouraged by studies in nonhuman primates in which cocaine is more readily self-administered by subordinate, rather than dominant, monkeys (19).

A key neural substrate underlying individual differences in drug vulnerability is thought to involve the brain dopamine (DA) systems, in particular the mesolimbic and mesocortical DA pathways innervating the nucleus accumbens and prefrontal cortex (19-22). Positron emission tomography (PET) studies in nonhuman primates have indicated a role for DA D2 receptors in determining individual differences in intravenous cocaine self-administration (19, 20). Specifically, low D2 receptor availability in the striatum inversely predicts subsequent levels of intravenous cocaine self-administration in rhesus monkeys (20), a result apparently similar to that seen in studies of human cocaine abusers (23).

However, it is not clear how individual differences in D2 receptor availability relate to a specific behavioral endophenotype or behavioral process that confers vulnerability to drug addiction. In addition, there have been few, if any, studies where DA release in vivo has been combined with PET estimates of D2 receptor availability. This is important because D2 receptor availability is influenced by both receptor density and competing DA release (24, 25). Thus, there is a need to conduct analogous PET studies in animals to investigate the predictive relationship between D2 receptor availability and trait behavioral markers of drug-abuse vulnerability.

We investigated the relevance of a spontaneously occurring form of impulsivity in outbred Lister hooded (LH) rats to intravenous cocaine self-administration and to underlying changes in striatal DA function, as measured by micro-PET and in vivo microdialysis (26). We defined impulsivity as high levels of anticipatory responses made before the presentation of a food-predictive, brief light stimulus in a five-choice serial reaction time (5-CSRT) task of sustained visual attention (27). Typically, 5-CSRT task impulsivity occurs in ~7% of male LH rats and, once identified, is a stable trait that persists throughout adulthood.

We first investigated the behavioral specificity of trait impulsivity on the 5-CSRT task and the correspondence of this trait to the high-responder (HR) drug-vulnerable phenotype described previously in rats by Piazza and colleagues (12). Trait impulsivity on the 5-CSRT task was characterized by a near-twofold increase in premature responding under both standard test conditions and when the intertrial interval (ITI) was increased to 7 s (Fig. 1A). In contrast to the HR rat, in our study trait impulsivity on the 5-CSRT task was inversely related to the level of locomotor activity measured in a novel environment [correlation coefficient (r) = 0.49, P = 0.02] (fig. S1).

Fig. 1
Behavioral attributes of trait impulsivity on the 5-CSRT task. (A) Impulsive rats exhibit high levels of premature responding on days when visual targets are presented either 5 s after trial initiation (days 1, 2, 4, and 5) or 7 s after trial initiation ...

Twelve cocaine-naïve adult male rats were then used to investigate DA D2/3 receptor availability in the ventral and dorsolateral striatum by means of micro-PET and the selective high-affinity DA D2/3 receptor antagonist [18F] fallypride (28). Six non-impulsive rats and six high-impulsive rats were prepared previously with an intravenous catheter. The ventral striatum was included as a region of interest (ROI), because the primary reinforcing and psychostimulant effects of drugs of abuse depend on the functional integrity of DA afferents to this region (29-31). In contrast, DA neurotransmission in the dorsolateral striatum mediates the persistent or compulsive forms of drug-seeking behavior (32), which is consistent with a role for this region in stimulus-response habit-based learning mechanisms (33, 34).

We found significantly reduced D2/3 receptor availability in the ventral striatum (P = 0.037) but not the dorsolateral striatum of high-impulsive rats as compared to non-impulsive rats (Fig. 2), and we also found a significant inverse correlation between D2/3 receptor availability in the ventral striatum and impulsivity (r = 0.58, P = 0.048) (fig. S2). An example of the quality of the data fit obtained with the simplified reference tissue model (35) is shown in fig. S3.

Fig. 2
Reduced binding potential (BP) of the selective D2/3 receptor antagonist [18F]fallypride in the ventral striatum of drug-naïve trait-impulsive rats (n = 6 rats) as compared to drug-naïve non-impulsive rats (n = 6). (Top) ROIs are shown ...

We also investigated the possibility that reduced [18F]fallypride binding potential in the ventral striatum was due to excessive release of DA in the nucleus accumbens. We postulated that enhanced DA release may have displaced [18F]fallypride from D2/3 receptors in this region, leading to an apparent reduction in D2/3 receptor availability. DA release and metabolism [inferred from levels of 3,4-dihydroxyphenylacetic acid and homovanillic acid (4-hydroxy-3-methoxyphenylacetic acid)] in the nucleus accumbens were not significantly different between impulsive rats and non-impulsive rats. There was also no significant difference in levels of the 5-hydroxytryptamine metabolite 5-hydroxyindoleacetic acid in this brain region (table S1). Thus, the most likely explanation for the significant reduction in D2/3 receptor availability in trait-impulsive rats was a decrease in the number of D2/3 receptors.

We next investigated the consequences of trait impulsivity for the acquisition and maintenance of intravenous cocaine self-administration. Intravenously catheterized rats that were screened previously for impulsivity on the 5-CSRT task, as well as their non-impulsive controls, were trained to acquire intravenous cocaine self-administration under a continuous-reinforcement schedule (fig. S4). Impulsive rats exhibited a clear increase in their rate of intravenous cocaine self-administration as compared to non-impulsive rats (Fig. 3), as well as a vertical shift in the cocaine dose-response curve (fig. S5).

Fig. 3
Differential escalation of intravenous cocaine self-administration in high-impulsive rats (n = 8) as compared to non-impulsive rats (n = 8). On the first 5 days, access to cocaine was restricted to 5 hours and a maximum of 50 infusions. After a withdrawal ...

In a final experiment, we investigated the effects of repeated intermittent withdrawal of cocaine on pretrained performance of the 5-CSRT task (Fig. 4). Our objective was to determine whether high rates of cocaine self-administration exhibited by trait-impulsive rats resulted in differential impairments in sustained visual attention, as compared to non-impulsive rats. We found that prolonged exposure of trait-impulsive rats to cocaine decreased levels of premature responding on the 5-CSRT task when the animals were tested in withdrawal (Fig. 4), but that it had no effect on other measures of performance, including attentional accuracy, omissions, and response latencies. Thus, one clear consequence of long-access cocaine exposure and subsequent cocaine withdrawal in trait-impulsive rats was a selective normalization of premature responding on the 5-CSRT task, relative to non-impulsive rats.

Fig. 4
Effects of intermittent intravenous cocaine self-administration in high-impulsive rats (n = 8) and non-impulsive rats (n = 8) on sustained visual attention on the 5-CSRT task. (A) Rats were withdrawn from intravenous cocaine self-administration on four ...

We have shown that individual differences in impulsive behavior on a five-choice task of sustained visual attention strongly predict individual variation in the rate of intravenous cocaine self-administration. Specifically, rats exhibiting trait impulsivity on the 5-CSRT task (27) showed a greater tendency for escalation of intravenous cocaine self-administration than did their non-impulsive counterparts. We also found unequivocal evidence for a significant inverse relationship between D2/3 receptor availability in the ventral striatum and trait impulsivity that could not be explained by abnormalities in pre-synaptic DA release and function in this region. These results expand on previous findings in abstinent human cocaine addicts (23, 36) by demonstrating that decreased D2 receptor availability in the striatum may be a predisposing neurobiological trait and not only a consequence of chronic cocaine exposure. They also add to the finding that D2 receptor availability in the striatum inversely predicts rates of intravenous cocaine self-administration in previously cocaine-naïve rhesus monkeys (20), by defining the characteristics of a drug-vulnerable phenotype in terms of a specific behavioral construct, as well as by underlying abnormalities in D2 receptor function in the striatum. Thus, the present data demonstrate that trait impulsiveness is a drug-vulnerable phenotype and highlight a potential overlapping involvement of D2-like DA receptors, which have been previously implicated in genetic studies of both impulsivity and vulnerability to drug-abuse disorders (37, 38).

Trait impulsivity on the 5-CSRT task is negatively correlated with novelty-induced locomotor activity and so is unlikely to be equivalent to the HR drug-vulnerable phenotype (12). In contrast to HR rats (12, 13), the high-impulsive rats in the present study did not acquire cocaine self-administration faster than the low-impulsive rats. Although impulsive female rats screened by means of a food-motivated delayed-discounting task acquired cocaine self-administration more rapidly than did low-impulsive rats (18), the high-impulsive rats acquired the delayed-discounting task more readily, suggesting that a more fundamental difference in instrumental learning may underpin the difference in the initiation of drug-taking behavior. HR rats also self-administer high doses of stimulants (12, 13), and so it is conceivable that this phenotype overlaps with the present high-impulsive animals to some extent. However, our findings specifically link trait impulsivity, rather than hyperactivity, to the maintenance and escalation of cocaine self-administration and to reduced D2/3 receptor binding in the nucleus accumbens.

Mutant mice lacking D2-like receptors show high rates of intravenous cocaine self-administration when high doses of cocaine are made available (39). Thus, D2 receptors may play a role in regulatory processes that normally act to limit excessive rates of cocaine self-administration. The decreased D2/3 receptor availability in the nucleus accumbens of high-impulsive rats may therefore contribute to increased cocaine self-administration. This finding may have broad relevance to a number of abused drugs in humans, including nicotine and opiates, where high consumption rates have also been linked to reduced D2 receptor function, specifically because of the presence of the D2 Taq I A1 allele (40, 41), which has previously been shown by PET to be associated with reduced D2 receptor density in the striatum (42).

Our results are consistent with the hypothesis that dysfunctional DA neurotransmission at D2-like receptors in the nucleus accumbens confers susceptibility to increased cocaine self-administration in high-impulsive rats. Recent findings in rhesus monkeys trained to self-administer cocaine support this view (19, 20), but there has been little evidence to date that D2 receptor dysregulation that is present either as a trait marker or induced by chronic cocaine exposure is restricted to the nucleus accumbens. Indeed, analogous PET studies in monkeys (19, 20, 43) and abstinent human cocaine addicts (23) report generalized reductions in D2 receptor availability throughout the striatum. In contrast, as in the present study, D2 receptor density and D2 mRNA content were found to be significantly reduced in the nucleus accumbens but not in the dorsal striatum or medial prefrontal cortex of HR rats (44).

The contrast between specific reductions in D2 receptor availability in the nucleus accumbens in rats before cocaine self-administration, as compared to the more divergent effects in the striatum after chronic exposure to cocaine self-administration, suggests the hypothesis that the ventral striatal changes confer susceptibility to cocaine taking, which subsequently affects DA neurotransmission in the dorsal striatum, with corresponding effects on the number of D2 receptors in that region (20, 23, 43). Thus, the development of psychostimulant drug addiction may represent a progression from initial impulsivity mediated by the nucleus accumbens to the development of compulsive habitual responding mediated by the dorsal striatum (32, 45).

Footnotes

Supporting Online Material

www.sciencemag.org/cgi/content/full/315/5816/1267/DC1

Materials and Methods

Figs. S1 to S5

Table S1

References

References and Notes

1. Chakroun N, Doron J, Swendsen J. Encephale. 2004;30:564. [PubMed]
2. Dawe S, Loxton NJ. Neurosci. Biobehav. Rev. 2004;28:343. [PubMed]
3. Sher KJ, Bartholow BD, Wood MD. J. Consult. Clin. Psychol. 2000;68:818. [PubMed]
4. Adams JB, et al. Am. J. Drug Alcohol Abuse. 2003;29:691. [PubMed]
5. Bolla KI, Rothman R, Cadet JL. J. Neuropsychiatry Clin. Neurosci. 1999;11:361. [PubMed]
6. Hester R, Garavan H. J. Neurosci. 2004;24:11017. [PubMed]
7. Jentsch JD, Taylor JR. Psychopharmacology. 1999;146:373. [PubMed]
8. Lyvers M. Exp. Clin. Psychopharmacol. 2000;8:225. [PubMed]
9. Paine TA, Dringenberg HC, Olmstead MC. Behav. Brain Res. 2003;147:135. [PubMed]
10. Dalley JW, et al. Psychopharmacology. 2005;182:579. [PubMed]
11. Dalley JW, et al. Neuropsychopharmacology. 2005;30:525. [PubMed]
12. Piazza PV, Deminiere JM, Le Moal M, Simon H. Science. 1989;245:1511. [PubMed]
13. Mantsch JR, Ho A, Schlussman SD, Kreek MJ. Psychopharmacology. 2001;157:31. [PubMed]
14. Larson EB, Carroll ME. Pharmacol. Biochem. Behav. 2005;82:590. [PubMed]
15. Morgan AD, Dess NK, Carroll ME. Psychopharmacology. 2005;178:41. [PubMed]
16. Gosnell BA. Psychopharmacology. 2000;149:286. [PubMed]
17. van der Kam EL, Ellenbroek BA, Cools AR. Neuropharmacology. 2005;48:685. [PubMed]
18. Perry JL, Larson EB, German JP, Madden GJ, Carroll ME. Psychopharmacology. 2005;178:193. [PubMed]
19. Morgan D, et al. Nat. Neurosci. 2002;5:169. [PubMed]
20. Nader MA, et al. Nat. Neurosci. 2006;9:1050. [PubMed]
21. Piazza PV, et al. Brain Res. 1991;567:169. [PubMed]
22. Tonissaar M, Herm L, Rinken A, Harro J. Neurosci. Lett. 2006;403:119. [PubMed]
23. Volkow ND, et al. Synapse. 1993;14:169. [PubMed]
24. Mach RH, et al. Pharmacol. Biochem. Behav. 1997;57:477. [PubMed]
25. Laruelle M, et al. Neuropsychopharmacology. 1997;17:162. [PubMed]
26. Materials and methods are available as supporting material on Science Online.
27. Robbins TW. Psychopharmacology. 2002;163:362. [PubMed]
28. Mukherjee J, et al. Nucl. Med. Biol. 1999;26:519. [PubMed]
29. Roberts DC, Corcoran ME, Fibiger HC. Pharmacol. Biochem. Behav. 1977;6:615. [PubMed]
30. Caine SB, Koob GF. J. Exp. Anal. Behav. 1994;61:213. [PMC free article] [PubMed]
31. Pettit HO, Ettenberg A, Bloom FE, Koob GF. Psychopharmacology. 1984;84:167. [PubMed]
32. Vanderschuren LJ, Di Ciano P, Everitt BJ. J. Neurosci. 2005;25:8665. [PubMed]
33. Packard MG, Knowlton BJ. Annu. Rev. Neurosci. 2002;25:563. [PubMed]
34. Yin HH, Knowlton BJ, Balleine BW. Eur. J. Neurosci. 2004;19:181. [PubMed]
35. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Neuroimage. 1997;6:279. [PubMed]
36. Martinez D, et al. Neuropsychopharmacology. 2004;29:1190. [PubMed]
37. Uhl GR. Ann. N. Y. Acad. Sci. 2004;1025:1. [PubMed]
38. Persico AM, Bird G, Gabbay FH, Uhl GR. Biol. Psychiatry. 1996;40:776. [PubMed]
39. Caine SB, et al. J. Neurosci. 2002;22:2977. [PubMed]
40. Comings DE, Blum K. Prog. Brain Res. 2000;126:325. [PubMed]
41. Shahmoradgoli Najafabadi M, et al. Am. J. Med. Genet. Neuropsychiatr. Genet. 2005;134:39. [PubMed]
42. Pohjalainen T, et al. Mol. Psychiatry. 1998;3:256. [PubMed]
43. Nader MA, et al. Neuropsychopharmacology. 2002;27:35. [PubMed]
44. Hooks MS, et al. J. Neurosci. 1994;14:6144. [PubMed]
45. Everitt BJ, Robbins TW. Nat. Neurosci. 2005;8:1481. [PubMed]
46. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. ed. 4 San Diego, CA: Academic Press; 1998. p. xxvi.
47. This research was supported by a joint award from the U.K. Medical Research Council (MRC) and the Wellcome Trust and by an MRC Pathfinder grant (G0401068) to J.W.D., B.J.E., and T.W.R. D.E.H.T. was supported by the Wellcome Trust. Y.P. was supported by a predoctoral Formación Investigadora scholarship from Generalitat de Catalunya. E.S.J.R. holds a Research Councils UK Academic Fellowship supported by the British Pharmacological Society Integrative Pharmacology Fund. E.R.M. was supported by a Gates Cambridge scholarship. We thank Merck, Sharp, & Dohme for originally donating the micro-PET scanner to Cambridge University.